Treatment of psoriasis with etanercept: the typical patient profile.

about

The totality-of-the-evidence approach to the development and assessment of GP2015, a proposed etanercept biosimilar.Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis.

P2860

Q38992643-78F5451E-3322-45FB-8B4A-9D15205D8947 Q40081220-A4875145-6845-4932-BB2A-B511AFC97E2E

P2860

Treatment of psoriasis with etanercept: the typical patient profile.

Item

http://www.wikidata.org/entity/Q38807058

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Treatment of psoriasis with etanercept: the typical patient profile.

@en

type

Item

label

Treatment of psoriasis with etanercept: the typical patient profile.

@en

prefLabel

Treatment of psoriasis with etanercept: the typical patient profile.

@en

P1476

Treatment of psoriasis with etanercept: the typical patient profile.

@en

P2093

G Girolomoni

http://www.w3.org/2001/XMLSchema#string

J C Prinz

http://www.w3.org/2001/XMLSchema#string

P2860

Immunogenicity of biotherapy used in psoriasis: the science behind the scenes

A patient-centred approach to biological treatment decision making for psoriasis: an expert consensus

Current and future management of psoriasis

Cost-effectiveness of psoriasis therapy with etanercept in Germany.

Duration of remission of psoriasis therapies.

Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.

The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men.

The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study.

A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy.

P304

1092-1099

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JDV.13662

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Luis Puig

P577

2016-04-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27073046

http://www.w3.org/2001/XMLSchema#string

Treatment of psoriasis with etanercept: the typical patient profile.

about

P2860

P2860

Treatment of psoriasis with etanercept: the typical patient profile.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698